Afrezza plus One Drop | Premium

ApprovedUNKNOWN
0 watching 0 views this week🔥 Hot
80
Hype Score

Development Stage

Pre-clinical
Phase 1
Phase 2
Phase 3
5
Approved
Indication / Disease

Diabetes Mellitus, Type 2

Conditions

Diabetes Mellitus, Type 2

Trial Timeline

Oct 5, 2017 → Dec 30, 2019

About Afrezza plus One Drop | Premium

Afrezza plus One Drop | Premium is a approved stage product being developed by MannKind Corp for Diabetes Mellitus, Type 2. The current trial status is unknown. This product is registered under clinical trial identifier NCT03313960. Target conditions include Diabetes Mellitus, Type 2.

Hype Score Breakdown

Clinical
30
Activity
20
Company
5
Novelty
10
Community
12

Clinical Trials (1)

NCT IDPhaseStatus
NCT03313960ApprovedUNKNOWN